Financial Contrast: Antibe Therapeutics (ATBPF) and Its Rivals


Share on StockTwits

Antibe Therapeutics (OTCMKTS: ATBPF) is one of 748 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Antibe Therapeutics to related businesses based on the strength of its risk, valuation, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Risk & Volatility

Antibe Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Antibe Therapeutics’ peers have a beta of 0.51, meaning that their average stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Antibe Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antibe Therapeutics -273.96% -150.49% -98.51%
Antibe Therapeutics Competitors -3,761.20% -189.29% -30.32%

Analyst Recommendations

This is a breakdown of recent ratings for Antibe Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antibe Therapeutics 0 0 3 0 3.00
Antibe Therapeutics Competitors 7805 21095 39598 1615 2.50

Antibe Therapeutics currently has a consensus target price of $1.45, indicating a potential downside of 55.32%. As a group, “Pharmaceutical preparations” companies have a potential upside of 29.25%. Given Antibe Therapeutics’ peers higher possible upside, analysts plainly believe Antibe Therapeutics has less favorable growth aspects than its peers.

Insider and Institutional Ownership

43.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Antibe Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Antibe Therapeutics $7.51 million -$14.54 million -6.49
Antibe Therapeutics Competitors $1.90 billion $219.78 million -3.74

Antibe Therapeutics’ peers have higher revenue and earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Antibe Therapeutics peers beat Antibe Therapeutics on 8 of the 13 factors compared.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.